CUE - Cue Biopharma, Inc.
Previous close
1.09
0.010 0.917%
Share volume: 1,709
Last Updated: Fri 27 Dec 2024 08:25:23 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.08
0.01
0.93%
Fundamental analysis
24%
Profitability
25%
Dept financing
10%
Liquidity
62%
Performance
17%
Performance
5 Days
3.85%
1 Month
-11.48%
3 Months
58.96%
6 Months
-22.86%
1 Year
-62.63%
2 Year
-61.29%
Key data
Stock price
$1.09
DAY RANGE
$1.03 - $1.10
52 WEEK RANGE
$0.48 - $3.20
52 WEEK CHANGE
-$59.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Daniel R. Passeri
Region: US
Website: cuebiopharma.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cuebiopharma.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cue Biopharma, Inc. develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.
Recent news